Early Access Programmes for Pharmaceuticals in Europe
10.11.2015 10:17
The EMA's PRIME (PRIority MEdicines) scheme is the latest attempt to accelerate
access for innovative drugs to the European market. This seminar addresses not only this programme, but also provides you with a thorough understanding of the various
programmes and methods currently facilitating pharmaceuticals' market access.
Termindetails
Wann
17.02.2016
von 09:00 bis 17:00
von 09:00 bis 17:00
Wo
Köln
Kontakttelefon
06221 500-680
Teilnehmer
This seminar addresses the needs of pharmaceutical industry employees who
work in medical affairs, market access or healthcare management.
Especially those dealing with market access strategies within Europe will
benefit from this course.
work in medical affairs, market access or healthcare management.
Especially those dealing with market access strategies within Europe will
benefit from this course.
Aims and objectives
The EMA's PRIME (PRIority MEdicines) scheme is the latest attempt to accelerate access for innovative drugs to the European market. This seminar addresses not only this programme, but also provides you with a thorough understanding of the various programmes and methods currently facilitating pharmaceuticals' market access.
After attending this seminar, you will have a core set of ideas on how to speed up market access for your products and know for exactly which programmes your product is eligible.
Topics
- Conditional approval
- Compassionate use and off-label use
- Named patient programme and expanded access programme
- French ATU - Best practice?
- Early access for orphans
- EMA's PRIME scheme
